GlycoMimetics' pivotal Phase 3 trial of uproleselan in R/R AML fails to meet primary endpoint of overall survival

CRESCENT BIOPHARMA, INC.

Phase 3 study (388 patients) of uproleselan + chemo did not achieve statistically significant improvement in overall survival vs chemo alone.
Median overall survival 13 months (uproleselan) vs 12.3 months (placebo).
NCI Phase 2/3 study in newly diagnosed AML remains ongoing; company will submit data to medical meeting.
Cash and cash equivalents $31.3M as of March 31, 2024, down from $41.8M at Dec 31, 2023.
Q1 2024 R&D expenses $6.0M, G&A $5.1M; shares outstanding 64.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CRESCENT BIOPHARMA, INC. reported preliminary financial results for first quarter of 2024.

Period: first quarter of 2024
Result: preliminary results

Exact text from the filing

On May 6, 2024, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing, in addition to the information described in Item 7.01 below, its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-006793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.